St. Luke's Medical Center, Philippines Report issue

Academic/Hospital Phase 1 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2010
NCT01486706
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Institute of Urology, St. Luke's Medical Center, Philippines | Michael E. Chua | St. Luke's Medical Center, Philippines | St. Luke's Medical Center - Quezon City

Active Ingredients

Drugs in Phase 4 Trials (2)

omeprazole (prilosec) (1 trial)

vonoprazan (Voquezna) (1 trial)

Drugs in Phase 3 Trials (2)

gabapentin (neurontin) (1 trial)

solifenacin (vesicare) (1 trial)

Drugs in Phase 1 Trials (1)

gen2 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Gastroesophageal Reflux (Phase 4)

Nocturia (Phase 3)

Urinary Bladder, Overactive (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5